Radiation&amp;ndash;Induced Haemorrhagic Cystitis

Crew, Jeremy; Jephcott, Catherine; Reynard, John

doi:10.1159/000049760

Cited by 92 publications

(74 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This neovascularization allows oxygen to be delivered to the ischemic tissue, facilitating re-epithelialization and tissue healing. 4 Therapeutic effects of HBO for radiation-induced hemorrhagic cystitis were initially described by Weiss in 1985. 5 To date, several case series of radiation-induced hemorrhagic cystitis have been reported 3,[6][7][8][9][10] ( Table 2), and most authors have concluded that HBO therapy is effective.…”

Section: Discussionmentioning

confidence: 99%

Hyperbaric oxygen therapy for radiation‐induced hemorrhagic cystitis

Yoshida¹,

Kawashima²,

Ujike³

et al. 2008

Int J of Urology

View full text Add to dashboard Cite

Hyperbaric oxygen (HBO) therapy has recently emerged as a potential primary option for the management of hemorrhagic cystitis. We review our experience treating hemorrhagic cystitis with HBO. Between January 2001 and May 2007, eight patients with radiation-induced hemorrhagic cystitis underwent HBO therapy. There were five men and three women with a mean age of 64.3 years (47-73). Radiation was given for local disease, and the mean dosage delivered was 56.6 Gy (42-70). The mean duration between the onset of hematuria and the beginning of HBO therapy was 8.9 months (3-34). Mean follow-up period was 15.5 months (2-31). Hematuria resolved completely in six of the eight patients, one of whom suffered recurrence of hematuria and was treated with HBO until the hematuria resolved again. The response rate was 75%, compatible with the previous reports, and no side-effects of HBO were noted. HBO treatment should be attempted for radiation-induced hemorrhagic cystitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Hyperbaric oxygen therapy for radiation‐induced hemorrhagic cystitis

Yoshida¹,

Kawashima²,

Ujike³

et al. 2008

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…Several studies have reported a 3-5% incidence of moderate to severe hematuria and 0.9% persisted hematuria following radiotherapy for prostate cancer [1,2] . Most of these patients can be treated conservatively with simple bladder irrigation, cystoscopic fulguration, intravesical agents or hyperbaric oxygen therapy [3] . Only a minority of patients have life-threatening bleeding, and in these patients conservative treatments are inadequate and radical surgery will be the last resort.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Radiation-Induced Hemorrhagic Cystitis with Laparoscopic Cystoprostatectomy

et al. 2006

View full text Add to dashboard Cite

Hemorrhagic cystitis can occur 6 months to 10 years after pelvic irradiation. Various palliative treatment alternatives may be unsuccessful in the management of severe hemorrhagic cystitis, so that in rare cases radical surgery will be the last resort.A 77-year-old man with persistent bleeding due to hemorrhagic cystitis after radiotherapy for prostate cancer was initially treated with conservative measures. All of these treatment methods were unsuccessful. His condition deteriorated and became life-threatening. As a last resort, laparoscopic cystoprostatectomy and mini-laparotomy ileal conduit diversion were successfully performed with no intraoperative or postoperative complications. To our knowledge, this is the first report on laparoscopic cystoprostatectomy for a patient with previous radiotherapy to the pelvis.

show abstract

“…Therefore, an effective treatment of LRTC is needed (14). Most of the few currently available conservative methods of LRTC treatment show inconsistent efficacy and no standard of care currently exists (10).…”

Section: Results Ofsf-12 (Pcs and Mcs) Reported As Mean Values Thementioning

confidence: 99%

Intravesical Hyaluronic Acid and Chondroitin Sulphate Improve Symptoms and Quality of Life in Patients with Late Radiation Tissue Cystitis: An Investigative Pilot Study

Sommariva¹,

Lazzeri

Abrate

et al. 2014

Eur J Inflamm

View full text Add to dashboard Cite

Intravesical hyaluronic acid (HA) and chondroitin sulphate (CS) instillation are effective for urinary tract infections (UTIs) and bladder pain syndrome. This study aimed to evaluate the tolerability, safety and efficacy of intravesical HA and CS instillation in patients with late radiation tissue cystitis (LRTC). In this pilot study, tolerability was reported as discontinuation or deviation of the protocol, safety as general or local side effects, efficacy as improvement of bladder capacity and frequency, quality of life (QoL) through the European Quality of Life 5-Dimensions (EQ-5D) (details at http://www.controlled-trials.com/ISRCTN37534393 ). Thirty-two patients with LRTC were enrolled. Twenty-seven patients (84.8%) received a mean of 12.2±0.3 months of instillation therapy. Only two patients (6.2%) developed a urinary tract infection from instillation, which required antibiotic treatment, nevertheless not compromising the therapy schedule. No male patient developed a urethral stricture. Intravesical instillation was associated with a significant increase (>50%) of bladder capacity from baseline (66.9ml) both at 3 months (101.9ml; p<0.001) and 12 months (174.4 ml; p<0.001). EQ-5D index significantly increased from baseline to both 3 and 12 months (0.26, 0.69 and 0.96, respectively; p<0.001). Intravesical co-administration of HA and CS improved bladder function, symptoms and QoL in patients with LRTC.

show abstract

Radiation–Induced Haemorrhagic Cystitis

Cited by 92 publications

References 95 publications

Hyperbaric oxygen therapy for radiation‐induced hemorrhagic cystitis

Hyperbaric oxygen therapy for radiation‐induced hemorrhagic cystitis

Treatment of Radiation-Induced Hemorrhagic Cystitis with Laparoscopic Cystoprostatectomy

Intravesical Hyaluronic Acid and Chondroitin Sulphate Improve Symptoms and Quality of Life in Patients with Late Radiation Tissue Cystitis: An Investigative Pilot Study

Contact Info

Product

Resources

About